What is Context Therapeutics?
Context Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing treatments for solid tumors. The company's lead candidate, CTIM-76, is an innovative anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody designed to harness T-cell immunity against CLDN6-expressing malignant cells. This therapeutic approach is further supported by a collaboration and licensing agreement with Integral Molecular, Inc., focusing on the development of CLDN6 bispecific monoclonal antibodies for oncology applications. Established in 2015 and headquartered in Philadelphia, Pennsylvania, Context Therapeutics is positioned within the competitive landscape of cancer drug development.
How much funding has Context Therapeutics raised?
Context Therapeutics has raised a total of $31.3M across 1 funding round:
Share Placement
$31.3M
Share Placement (2021): $31.3M, investors not publicly disclosed
What's next for Context Therapeutics?
The recent major strategic investment signals a pivotal phase for Context Therapeutics, likely enabling the acceleration of its clinical development pipeline, particularly for its bispecific antibody candidate. This infusion of capital is expected to facilitate further research, potential expansion of its therapeutic targets, and progression through regulatory pathways. The company's focus on CLDN6, a target with significant potential in various solid tumors, positions it for substantial growth and impact in the oncology sector.
See full Context Therapeutics company page
